24 completed, 4 terminated, 2 active not recruiting, 1 unknown. 15 Phase 2, 12 Phase 1, 4 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 10, Terminated 3, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 12 | Completed 12 |
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
| Not applicable | 1 | Unknown 1 |
Follow ZD4054: new trials by email Literature Review of ZD4054 trials Research Report on ZD4054
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food Zibotentan/Dapagliflozin FDC - Healthy Participants | Phase 1 | Completed | AstraZeneca | 26 | 2026-02-16 | 2026-04-13 |
| A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria Zibotentan/Dapagliflozin, Dapagliflozin - Chronic Kidney Disease With High Proteinuria | Phase 2 | Active not recruiting | AstraZeneca | 224 | 2025-05-07 | 2026-09-02 |
| A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants Zibotentan - Liver Cirrhosis | Phase 1 | Completed | AstraZeneca | 30 | 2024-12-05 | 2025-12-04 |
| A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin - Liver Cirrhosis | Phase 2 | Completed | AstraZeneca | 73 | 2024-02-15 | 2026-01-20 |
| Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) Zibotentan/Dapagliflozin, Dapagliflozin - Chronic Kidney Disease With High Proteinuria | Phase 3 | Active not recruiting | AstraZeneca | 1835 | 2023-11-07 | 2026-10-13 |
| Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria Zibotentan, Dapagliflozin, Placebo - Chronic Kidney Diseases | Phase 2 | Completed | University Medical Center Groningen | 42 | 2022-10-06 | 2025-04-30 |
| Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential. Zibotentan, EE/LNG - Healthy Female Participants | Phase 1 | Completed | AstraZeneca | 24 | 2022-08-24 | 2023-02-09 |
| A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment Zibotentan - Hepatic Impairment, Renal Impairment | Phase 1 | Completed | AstraZeneca | 12 | 2021-11-10 | 2022-01-27 |
| Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B) - Chronic Kidney Disease | Phase 1 | Completed | AstraZeneca | 27 | 2021-07-29 | 2021-11-23 |
| Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) Zibotentan, Dapagliflozin, Placebo - Chronic Kidney Disease | Phase 2 | Completed | AstraZeneca | 542 | 2021-04-28 | 2024-07-30 |
| Precision Medicine With Zibotentan in Microvascular Angina Zibotentan, Placebo oral tablet - Microvascular Angina | Phase 2 | Completed | NHS Greater Glasgow and Clyde | 225 | 2019-10-18 | 2023-08-04 |
| Zibotentan Better Renal Scleroderma Outcome Study Zibotentan - Scleroderma, Scleroderma Renal Crisis | Phase 2 | Completed | University College, London | 27 | 2014-10-01 | 2017-10-31 |
| Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication Zibotentan (ZD4054), placebo - Peripheral Arterial Disease, Intermittent Claudication | Phase 2 | Completed | University of Virginia | 31 | 2013-06-01 | 2016-08-02 |
| ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer ZD4054 - Prostate Cancer | Phase 2 | Terminated | University of Wisconsin, Madison | 6 | 2010-04-01 | 2019-11-21 |
| Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer FOLFIRI regimen, fluorouracil, irinotecan hydrochloride - Colorectal Cancer | Phase 2 | Completed | Cardiff University | 111 | 2010-04-01 | 2014-07-08 |
| A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer ZD4054 - Prostate Cancer, Metastasis | Phase 2 | Terminated | Aarhus University Hospital | 24 | 2009-10-01 | 2014-01-08 |
| 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies ZD4054 (Zibotentan) - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 15 | 2009-10-01 | 2011-05-19 |
| Window Study of ZD4054 in Metastatic Prostate Cancer ZD4054 - Prostate Cancer, Metastasis | Not applicable | Unknown | The Christie NHS Foundation Trust | 30 | 2009-07-01 | 2010-07-23 |
| ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer ZD4054 Zibotentan, Paclitaxel, Carboplatin - Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy | Phase 2 | Terminated | AstraZeneca | 120 | 2009-06-01 | 2012-08-07 |
| ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study ZD4054, Pemetrexed, Placebo - Non Small Cell Lung Cancer, Lung Cancer | Phase 2 | Completed | AstraZeneca | 66 | 2008-08-01 | 2012-06-06 |
Showing 20 of 32. Sign in to see all of them.
Prostatic Neoplasms (9) · Renal Insufficiency, Chronic (7) · Neoplasm Metastasis (4) · Kidney Diseases (3) · Liver Cirrhosis (2) · Albuminuria (1) · Angina Pectoris (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Diabetic Nephropathies (1) · Fibrosis (1) · Hypersensitivity (1) · Intermittent Claudication (1)
AstraZeneca (23) · Cardiff University (2) · Aarhus University Hospital (1) · NHS Greater Glasgow and Clyde (1) · The Christie NHS Foundation Trust (1) · University College, London (1) · University Medical Center Groningen (1) · University of Virginia (1) · University of Wisconsin, Madison (1)
United States (17) · United Kingdom (15) · Germany (8) · Australia (7) · Canada (7) · Denmark (7) · Italy (7) · Netherlands (7) · Poland (7) · Czechia (6) · France (6) · Argentina (5) · Brazil (5) · Japan (5) · South Africa (5)
Thomas Morris (3) · Anne Thomas, MD (1) · Blanka Cieslarova, MD (1) · Brian H Annex, MD (1) · Christos Chouaid, MD, Prof (1) · Dago Mazur (1) · David C Wheeler, MB ChB, MD, FRCP (1) · David Wessels (1) · Glenn Liu, M.D. (1) · Helen Lin (1) · Hiddo J Lambers Heerspink, PhD, PharmD (1) · Ian Thomas (1) · Jamie P. Dwyer, M.D. (1) · Joel B Nelson, MD (1)
PMID 39352861, PMID 19042080, PMID 20678684, PMID 21414193, PMID 23234805, PMID 23569308, PMID 25128349, PMID 33990507, PMID 35650639, PMID 37632201, PMID 37801266, PMID 37931629, PMID 39217504, PMID 41430169, PMID 41687797, PMID 41805697
2023 (2)